Agilent Technologies, Inc. (A)AAgilent Technologies, Inc.

Financials

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Apr 2026	Quarter ended Jan 2026	Quarter ended Oct 2025	Quarter ended Jul 2025	Quarter ended Apr 2025	Quarter ended Jan 2025	Quarter ended Oct 2024	Quarter ended Jul 2024
Revenue	7.23B	1.83B	1.80B	1.86B	1.74B	1.67B	1.68B	1.70B	1.58B
Cost of Goods Sold	3.40B	826.00M	852.00M	897.00M	824.00M	802.00M	782.00M	785.00M	723.00M
Gross Profit	3.83B	1.01B	946.00M	964.00M	914.00M	866.00M	899.00M	916.00M	855.00M
Gross Profit Margin	53.0%	55.0%	52.6%	51.8%	52.6%	51.9%	53.5%	53.9%	54.2%
Total Operating Expenses	2.28B	610.00M	593.00M	521.00M	554.00M	566.00M	523.00M	508.00M	522.00M
Research & Development	473.00M	126.00M	117.00M	119.00M	111.00M	112.00M	113.00M	111.00M	127.00M
Selling, General & Administrative	1.79B	465.00M	476.00M	428.00M	417.00M	454.00M	410.00M	397.00M	395.00M
Operating Income (EBIT)	1.55B	399.00M	353.00M	443.00M	360.00M	300.00M	376.00M	408.00M	333.00M
Operating Margin	21.5%	21.7%	19.6%	23.8%	20.7%	18.0%	22.4%	24.0%	21.1%
Income Before Tax (EBT)	1.58B	408.00M	364.00M	442.00M	366.00M	260.00M	367.00M	401.00M	343.00M
Interest Income	61.00M	13.00M	15.00M	17.00M	16.00M	14.00M	15.00M	24.00M	19.00M
Interest Expense	105.00M	25.00M	25.00M	27.00M	28.00M	29.00M	28.00M	32.00M	22.00M
Other Income/Expense	25.00M	9.00M	11.00M	-1.00M	6.00M	-40.00M	-9.00M	-7.00M	10.00M
Net Income	1.41B	339.00M	305.00M	434.00M	336.00M	215.00M	318.00M	351.00M	282.00M
Income Tax Expense	166.00M	69.00M	59.00M	8.00M	30.00M	45.00M	49.00M	50.00M	61.00M
Net Profit Margin	19.6%	18.5%	17.0%	23.3%	19.3%	12.9%	18.9%	20.6%	17.9%
EBITDA	1.83B	466.00M	420.00M	514.00M	432.00M	373.00M	448.00M	477.00M	396.00M
EBITDA Margin	25.3%	25.4%	23.4%	27.6%	24.9%	22.4%	26.7%	28.0%	25.1%
Depreciation & Amortization	277.00M	67.00M	67.00M	71.00M	72.00M	73.00M	72.00M	69.00M	63.00M
EPS Basic	4.99	1.20	1.08	1.53	1.18	0.75	1.12	1.23	0.97
EPS Diluted	4.98	1.20	1.07	1.53	1.18	0.75	1.11	1.22	0.97
Shares Outstanding	283.00M	283.00M	283.00M	283.00M	285.00M	285.00M	285.00M	290.00M	290.00M
Diluted Shares Outstanding	284.00M	284.00M	284.00M	284.00M	285.00M	285.00M	287.00M	291.00M	291.00M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	10/31/2025	10/31/2024	10/31/2023	10/31/2022	10/31/2021	10/31/2020	10/31/2019	10/31/2018
Revenue	6.95B	6.51B	6.83B	6.85B	6.32B	5.34B	5.16B	4.91B
Cost of Goods Sold	3.31B	2.98B	3.37B	3.13B	2.91B	2.50B	2.36B	2.23B
Gross Profit	3.64B	3.54B	3.46B	3.72B	3.41B	2.84B	2.81B	2.69B
Gross Profit Margin	52.4%	54.3%	50.7%	54.4%	53.9%	53.1%	54.3%	54.7%
Total Operating Expenses	2.16B	2.05B	2.12B	2.10B	2.06B	1.99B	1.86B	1.78B
Research & Development	455.00M	479.00M	481.00M	467.00M	441.00M	495.00M	404.00M	385.00M
Selling, General & Administrative	1.71B	1.52B	1.63B	1.64B	1.62B	1.50B	1.46B	1.37B
Operating Income (EBIT)	1.48B	1.49B	1.35B	1.62B	1.35B	846.00M	941.00M	904.00M
Operating Margin	21.3%	22.9%	19.8%	23.6%	21.3%	15.8%	18.2%	18.4%
Income Before Tax (EBT)	1.44B	1.52B	1.34B	1.50B	1.36B	842.00M	919.00M	946.00M
Interest Income	62.00M	80.00M	51.00M	9.00M	2.00M	8.00M	36.00M	38.00M
Interest Expense	112.00M	96.00M	95.00M	84.00M	81.00M	78.00M	74.00M	75.00M
Other Income/Expense	-44.00M	33.00M	-11.00M	-114.00M	13.00M	-4.00M	-22.00M	42.00M
Net Income	1.30B	1.29B	1.24B	1.25B	1.21B	719.00M	1.07B	316.00M
Income Tax Expense	132.00M	232.00M	99.00M	250.00M	150.00M	123.00M	-152.00M	630.00M
Net Profit Margin	18.8%	19.8%	18.1%	18.3%	19.1%	13.5%	20.7%	6.4%
EBITDA	1.77B	1.75B	1.62B	1.94B	1.67B	1.15B	1.18B	1.11B
EBITDA Margin	25.4%	26.8%	23.7%	28.3%	26.4%	21.6%	22.8%	22.7%
Depreciation & Amortization	288.00M	257.00M	271.00M	317.00M	321.00M	308.00M	238.00M	210.00M
EPS Basic	4.59	4.44	4.22	4.19	3.98	2.33	3.41	0.98
EPS Diluted	4.57	4.43	4.19	4.18	3.94	2.30	3.37	0.97
Shares Outstanding	283.00M	290.00M	294.00M	299.00M	304.00M	309.00M	314.00M	321.00M
Diluted Shares Outstanding	284.00M	291.00M	296.00M	300.00M	307.00M	312.00M	318.00M	325.00M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Agilent Technologies, Inc.

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Santa Clara, CA

18,100 employees

www.agilent.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Padraig McDonnell

View full financials